Your shopping cart is currently empty

CHK1-IN-9 (compound 11) is an orally active CHK1 inhibitor with an IC50 of 0.55 nM. It enhances the effects of DNA-damaging agents on tumor cells and exhibits synergistic anticancer activity with Gemcitabine.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | CHK1-IN-9 (compound 11) is an orally active CHK1 inhibitor with an IC50 of 0.55 nM. It enhances the effects of DNA-damaging agents on tumor cells and exhibits synergistic anticancer activity with Gemcitabine. |
| Targets&IC50 | Chk1:0.55 nM |
| In vitro | CHK1-IN-9 (compound 11) demonstrates antiproliferative effects on tumor cells at concentrations of 11.11, 33.33, 100, and 300 nM over a 16-hour period, with an IC50 value of 202 nM specifically for MV-4-11 cells. |
| In vivo | CHK1-IN-9 (compound 11) administered at 30 mg/kg daily for 21 consecutive days, either intravenously or orally, results in a tumor growth inhibition (TGI) of 20.6% when used alone on HT-29 xenograft mouse models. When combined with Gemcitabine, it demonstrates enhanced antitumor activity with a TGI of 42.8%. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.